X0508 4 2026-03-12 false 0001690585 Dianthus Therapeutics, Inc. /DE/ DNTH 0001669866 Garcia Marino C/O DIANTHUS THERAPEUTICS, INC. 7 TIMES SQUARE, 43RD FLOOR NEW YORK NY 10036 true true false false CEO AND PRESIDENT true Common Stock 2026-03-12 4 M false 122918 6.70 A 122918 D Common Stock 2026-03-12 4 S false 43505 80.69 D 79413 D Common Stock 2026-03-12 4 S false 65517 81.74 D 13896 D Common Stock 2026-03-12 4 S false 12796 82.60 D 1100 D Common Stock 2026-03-12 4 S false 200 83.38 D 900 D Common Stock 2026-03-12 4 S false 900 85.53 D 0 D Stock Option (Right to Buy) 6.70 2026-03-12 4 M false 122918 0 D 2031-11-03 Common Stock 122918 59741 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.29 to $81.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.29 to $82.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.29 to $83.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The shares of common stock underlying this stock option award vested as to 25% of the shares on November 1, 2022, with the remaining three quarters vested in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. /s/ Adam Veness, as attorney-in-fact for Marino Garcia 2026-03-13